Dashboard
Manage Tickers

AXSMAxsome Therapeutics, Inc.

Nasdaq axsome.com


$ 73.89 $ -0.37 (-0.5 %)    

Friday, 10-May-2024 11:10:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.12 $ -1.81 (-0.41 %)
DIA $ 394.59 $ -0.67 (-0.17 %)
SPY $ 520.19 $ -1.36 (-0.26 %)
TLT $ 90.03 $ -0.28 (-0.31 %)
GLD $ 218.18 $ -1.54 (-0.7 %)
$ 73.68
$ 74.26
$ 73.60 x 100
$ 74.06 x 100
$ 73.76 - $ 75.50
$ 55.02 - $ 98.40
1,071,100
na
3.49B
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-02-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-15-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-07-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-07-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-11-2016 03-31-2016 10-Q
34 03-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mizuho-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-106
Mizuho Maintains Buy on Axsome Therapeutic...
05/08/2024 11:12:59

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $10...

citigroup-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-125
Citigroup Maintains Buy on Axsome Therapeu...
05/07/2024 17:17:11

Citigroup analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $127 t...

baird-maintains-outperform-on-axsome-therapeutics-raises-price-target-to-112
Baird Maintains Outperform on Axsome Thera...
05/07/2024 10:46:44

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $10...

hc-wainwright--co-reiterates-buy-on-axsome-therapeutics-maintains-190-price-target
HC Wainwright & Co. Reiterates Buy on Axso...
05/07/2024 10:32:07

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $19...

axsome-therapeutics-q1-2024-gaap-eps-144-misses-121-estimate-sales-74999m-beat-73295m-estimate
Axsome Therapeutics Q1 2024 GAAP EPS $(1.4...
05/06/2024 11:01:59

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of...

peeling-back-the-layers-exploring-axsome-therapeutics-through-analyst-insights
Peeling Back The Layers: Exploring Axsome ...
04/29/2024 14:01:24

morgan-stanley-upgrades-axsome-therapeutics-to-overweight-raises-price-target-to-115
Morgan Stanley Upgrades Axsome Therapeutic...
04/29/2024 09:27:02

Morgan Stanley analyst Vikram Purohit upgrades Axsome Therapeutics (NASDAQ:AXSM) from Equal-Weight to Overweight and raises ...

analyst-ratings-for-axsome-therapeutics
Analyst Ratings For Axsome Therapeutics
04/10/2024 16:00:19

cantor-fitzgerald-reiterates-overweight-on-axsome-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/10/2024 13:35:22

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

hc-wainwright--co-maintains-buy-on-axsome-therapeutics-maintains-190-price-target
HC Wainwright & Co. Maintains Buy on Axsom...
04/02/2024 12:53:14

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $190...

axsome-therapeutics-has-initiated-engage-phase-3-trial-of-solriamfetol-an-investigational-treatment-for-binge-eating-disorder-in-adults
Axsome Therapeutics Has Initiated ENGAGE P...
04/01/2024 11:28:02

mizuho-maintains-buy-on-axsome-therapeutics-raises-price-target-to-109
Mizuho Maintains Buy on Axsome Therapeutic...
03/28/2024 14:06:59

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $10...

truist-securities-maintains-buy-on-axsome-therapeutics-maintains-150-price-target
Truist Securities Maintains Buy on Axsome ...
03/26/2024 13:23:19

Truist Securities analyst Joon Lee maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.

tesla-to-120-here-are-10-top-analyst-forecasts-for-tuesday
Tesla To $120? Here Are 10 Top Analyst For...
03/26/2024 12:30:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

rbc-capital-maintains-outperform-on-axsome-therapeutics-raises-price-target-to-128
RBC Capital Maintains Outperform on Axsome...
03/26/2024 12:09:24

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...

citigroup-maintains-buy-on-axsome-therapeutics-raises-price-target-to-127
Citigroup Maintains Buy on Axsome Therapeu...
03/26/2024 11:34:40

Citigroup analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $125 t...

hc-wainwright--co-maintains-buy-on-axsome-therapeutics-raises-price-target-to-190
HC Wainwright & Co. Maintains Buy on Axsom...
03/26/2024 10:15:15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the pri...

whats-going-on-neurology-focused-axsome-therapeutics-stock-on-monday
What's Going On Neurology-Focused Axsome T...
03/25/2024 16:03:43

Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant ...

axsome-therapeutics-shares-are-trading-higher-the-companys-axs-12-achieved-primary-endpoint-in-the-symphony-phase-3-trial-in-narcolepsy
Axsome Therapeutics shares are trading hig...
03/25/2024 10:41:32

axsome-therapeutics-axs-12-reboxetine-achieved-the-primary-endpoint-and-significantly-reduced-the-frequency-of-cataplexy-attacks-as-compared-to-placebo-in-narcolepsy-patients-in-symphony-phase-3-trial
Axsome Therapeutics' AXS-12 (Reboxetine) A...
03/25/2024 10:32:12

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy se...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION